Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

• Main Authors: Gang Shen (Author), Lei Shi (Author), Xin Tian (Author), Depei Huang (Author), Hao Chen (Author), Chan Gao (Author), Xudong Shen (Author), Hushan Zhang (Author)
• Format: Knjiga
• Izdano: Frontiers Media S.A., 2021-12-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatm...